Injectable human recombinant collagen matrices limit adverse
remodeling and improve cardiac function after myocardial
infarction

J 2019

Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction

MCLAUGHLIN, S; B MCNEILL; J PODREBARAC; K HOSOYAMA; Veronika SEDLÁKOVÁ et al.

Základní údaje

Originální název

Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction

Autoři

MCLAUGHLIN, S; B MCNEILL; J PODREBARAC; K HOSOYAMA; Veronika SEDLÁKOVÁ; G CRON; D SMYTH; R SEYMOUR; K GOEL; WB LIANG; KJ RAYNER; M RUEL; EJ SUURONEN a EI ALARCON

Vydání

Nature Communications, London, Nature Publishing Group, 2019, 2041-1723

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 12.121

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1038/s41467-019-12748-8

UT WoS

000492835100004

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2022 10:06, MUDr. Veronika Sedláková, Ph.D.

Anotace

V originále

Despite the success of current therapies for acute myocardial infarction (MI), many patients still develop adverse cardiac remodeling and heart failure. With the growing prevalence of heart failure, a new therapy is needed that can prevent remodeling and support tissue repair. Herein, we report on injectable recombinant human collagen type I (rHCI) and type III (rHCIII) matrices for treating MI. Injecting rHCI or rHCIII matrices in mice during the late proliferative phase post-MI restores the myocardium's mechanical properties and reduces scar size, but only the rHCI matrix maintains remote wall thickness and prevents heart enlargement. rHCI treatment increases cardiomyocyte and capillary numbers in the border zone and the presence of pro-wound healing macrophages in the ischemic area, while reducing the overall recruitment of bone marrow monocytes. Our findings show functional recovery post-MI using rHCI by promoting a healing environment, cardiomyocyte survival, and less pathological remodeling of the myocardium.

Citovat

MCLAUGHLIN, S; B MCNEILL; J PODREBARAC; K HOSOYAMA; Veronika SEDLÁKOVÁ; G CRON; D SMYTH; R SEYMOUR; K GOEL; WB LIANG; KJ RAYNER; M RUEL; EJ SUURONEN a EI ALARCON. Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction. Nature Communications. London: Nature Publishing Group, 2019, roč. 10, 14 s. ISSN 2041-1723. Dostupné z: https://doi.org/10.1038/s41467-019-12748-8.

@article{1703796,
   author = {McLaughlin, S and McNeill, B and Podrebarac, J and Hosoyama, K and Sedláková, Veronika and Cron, G and Smyth, D and Seymour, R and Goel, K and Liang, WB and Rayner, KJ and Ruel, M and Suuronen, EJ and Alarcon, EI},
   article_location = {London},
   doi = {https://doi.org/10.1038/s41467-019-12748-8},
   language = {eng},
   issn = {2041-1723},
   journal = {Nature Communications},
   title = {Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction},
   volume = {10},
   year = {2019}
}

TY  - JOUR
ID  - 1703796
AU  - McLaughlin, S - McNeill, B - Podrebarac, J - Hosoyama, K - Sedláková, Veronika - Cron, G - Smyth, D - Seymour, R - Goel, K - Liang, WB - Rayner, KJ - Ruel, M - Suuronen, EJ - Alarcon, EI
PY  - 2019
TI  - Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction
JF  - Nature Communications
VL  - 10
PB  - Nature Publishing Group
SN  - 20411723
N2  - Despite the success of current therapies for acute myocardial infarction (MI), many patients still develop adverse cardiac remodeling and heart failure. With the growing prevalence of heart failure, a new therapy is needed that can prevent remodeling and support tissue repair. Herein, we report on injectable recombinant human collagen type I (rHCI) and type III (rHCIII) matrices for treating MI. Injecting rHCI or rHCIII matrices in mice during the late proliferative phase post-MI restores the myocardium's mechanical properties and reduces scar size, but only the rHCI matrix maintains remote wall thickness and prevents heart enlargement. rHCI treatment increases cardiomyocyte and capillary numbers in the border zone and the presence of pro-wound healing macrophages in the ischemic area, while reducing the overall recruitment of bone marrow monocytes. Our findings show functional recovery post-MI using rHCI by promoting a healing environment, cardiomyocyte survival, and less pathological remodeling of the myocardium.
ER  -

MCLAUGHLIN, S; B MCNEILL; J PODREBARAC; K HOSOYAMA; Veronika SEDLÁKOVÁ; G CRON; D SMYTH; R SEYMOUR; K GOEL; WB LIANG; KJ RAYNER; M RUEL; EJ SUURONEN a EI ALARCON. Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction. \textit{Nature Communications}. London: Nature Publishing Group, 2019, roč.~10, 14 s. ISSN~2041-1723. Dostupné z: https://doi.org/10.1038/s41467-019-12748-8.

Přehled o publikaci